{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-005186","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.091362+00:00","generated_at":"2026-06-24T07:18:05.577138+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PharmaCyte Biotech rejects Iroquois Capital's consent solicitation to control board and cash reserves","bullets":["Iroquois Capital, a 7% holder, seeks to expand board from 7 to 15 and elect 8 nominees to gain control of $80M+ cash.","Company says Iroquois proposals are full of factual inaccuracies and would disenfranchise shareholders; urges ignoring consent cards.","PharmaCyte states Iroquois slate has limited biopharma experience; claims seven similar Iroquois board additions led to avg 30%+ stock decline.","Company reports ~90% of FDA clinical hold requests completed; two-phase pig study is last major item, progress could be jeopardized.","PharmaCyte engaged in settlement talks with Iroquois but they rejected; Iroquois bought shares at low price and sold immediately, per company."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-005186","json":"https://secwatch.observer/filing/0001683168-22-005186.json","markdown":"https://secwatch.observer/filing/0001683168-22-005186.md","text":"https://secwatch.observer/filing/0001683168-22-005186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005186/0001683168-22-005186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316822005186/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:18:05.577138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}